Company: SION
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001193125-25-018825
Chunk: 353

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-03
Form: S-1/A
Chunk 353
---
APEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT (in thousands, except share amounts) (Unaudited)

|                                                                     |     | Series Seed     
 Preferred Stock 
 Shares          |           |     | Amount |        |     | Series A        
 Preferred Stock 
 Shares          |           |     | Amount |        |     | Series B        
 Preferred Stock 
 Shares          |            |     | Amount |         |     | Series C        
 Preferred Stock 
 Shares          |            |     | Amount |         |     | Common Stock 
 Shares       |           |     | Amount |   |     | Additional 
 Paid-In    
 Capital    |        |     | Accumulated   
 Other         
 Comprehensive 
 Income        |     |     | Accumulated 
 Deficit     |          |   |     | Total         
 Stockholders’ 
 Deficit       |          |   |
|:--------------------------------------------------------------------|:----|:----------------|----------:|:----|:-------|-------:|:----|:----------------|----------:|:----|:-------|-------:|:----|:----------------|-----------:|:----|:-------|--------:|:----|:----------------|-----------:|:----|:-------|--------:|:----|:-------------|----------:|:----|:-------|--:|:----|:-----------|-------:|:----|:--------------|----:|:----|:------------|:---------|:--|:----|:--------------|---------:|:--|
| Balance as of December 31, 2023                                     |     |                 | 3,963,963 |     | $      | 13,014 |     |                 | 5,704,161 |     | $      | 25,235 |     |                 | 11,370,621 |     | $      | 110,791 |     |                 |          — |     | $      |       — |     |              | 3,050,863 |     | $      | 2 |     | $          |  4,515 |     | $             |   — |     | $           | (119,398 | ) |     | $             | (114,881 | ) |
| Issuance of Series C Preferred Stock, net of issuance costs of $528 |     |                 |         — |     |        |